Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 27933632.
- Also identified by DOI 10.1002/lary.26426.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Therapeutic monocolonal antibodies (MAbs) are a new, rapidly growing class of medications that frequently have poorly characterized side-effect profiles. We present a patient who developed inflammatory lesions of the vocal folds in temporal relation to the initiation of alirocumab. Lesions of the vocal folds represent a previously unreported adverse effect of alirocumab therapy, making it the second MAb documented with such a side effect. The potential laryngeal effects of alirocumab specifically, and of MAbs more broadly, warrant investigation. Laryngoscope, 127:1652-1654, 2017.
Medical subject headings
- Antibodies, Monoclonal
- Laryngitis